6168.HK

Shares of jeweler Zhou Liu Fu Jewellery Co. Ltd. (6168.HK) rose in their Hong Kong trading debut on Thursday, opening up 11% and continuing to rise during the morning session to close up 15% at HK$27.60 by the midday break.

The company sold 46.8 million shares for HK$24 apiece to raise net proceeds of about HK$1.2 billion ($153 million). The public offering for local Hong Kong investors was oversubscribed by 710 times, while the international placement was oversubscribed by nearly 13 times.

Zhou Liu Fu had 4,129 brick-and-mortar stores by the end of last year, including franchised and company-owned outlets. It reported revenue of 5.72 billion yuan ($797 million) last year, up 11% year-on-year, while its profit climbed 7.1% to 710 million yuan.

Zhou Liu Fu’s IPO prospectus discloses that its brand may be vulnerable to counterfeiting or imitation. In fact, since its founding, the company’s Chinese name has been accused of imitating veteran Hong Kong jeweler Chow Tai Fook (1929.HK). Zhou Liu Fu ‘s Chinese name appears to combine elements from both Chow Tai Fook (1929.HK) and Luk Fook Jewellery (0590.HK), another veteran Hong Kong chain.

By Lau Chi Hang

To subscribe to Bamboo Works weekly free newsletter, clickhere

Recent Articles

Illustration of Luckin and Costa coffee being tasted

Luckin Coffee eyes global leap as China’s Double 11 loses its luster

Luckin could be preparing a bid for Costa Coffee. What's driving this potential deal, and what are its chances for success? And this year's Double 11 festival looks like a dud, with most big e-commerce companies failing to publish any big numbers. What does the future hold for this fast-fading shopping fest?
So-Young runs cosmetic surgery clinics

Can So-Young find new youth in bricks and mortar?

The cosmetic surgery specialist’s top line is growing as it opens new ‘light medical aesthetic’ clinics, but its bottom line is sagging as its older platform business evaporates Key Takeaways:…
CSPC delivered lower nine-month revenues and profits

CSPC feels the pain from sweeping cuts in drug prices

The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…